cd /news/ai-safety/in-support-of-mandatory-nucleic-acid… · home topics ai-safety article
[ARTICLE · art-21082] src=screendna.org pub= topic=ai-safety verified=true sentiment=· neutral

In Support of Mandatory Nucleic Acid Synthesis Screening and Recordkeeping

A coalition of AI and biotechnology leaders, including Demis Hassabis, Sam Altman, and Dario Amodei, is urging Congress to mandate screening and recordkeeping for all orders of synthetic nucleic acids and DNA synthesis equipment. The group warns that rapid advances in AI are eroding knowledge barriers that have historically prevented bad actors from obtaining biological weapons, making voluntary industry safeguards insufficient. The signatories argue that mandatory screening is a well-understood, minimally disruptive measure that would establish a consistent national standard and deter misuse of dual-use biotechnology.

read6 min publishedJun 4, 2026

As life sciences researchers, builders of AI and biotechnology, and experts with a wide range of views on how to approach AI policy, we call on legislators to make screening of orders for synthetic nucleic acids — and the equipment needed to make them — mandatory.

The ability to order synthetic DNA online has accelerated vaccine development, powered basic research, and made it possible for small teams to access capabilities that used to be confined to major institutions. Since the publication of protocols to reconstruct viruses from strands of DNA more than two decades ago, it has also been recognized as a point in the biotechnology supply chain where a bad actor could cause outsized harm. Recognizing the vulnerability, synthesis companies formed the International Gene Synthesis Consortium in 2009 to develop and implement voluntary safeguards against misuse.

While the issue is not new, the pace of progress in artificial intelligence is. AI systems now outperform PhD-level virologists on questions about highly technical laboratory procedures in their own domains of expertise. The evidence about what this means for present-day biosecurity threats is genuinely mixed, but the trend is hard to dispute. AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode. Support for screening does not depend on any particular view of AI; the biosecurity case has been recognized by scientists and governments for decades. Screening is also one of the best understood and least disruptive biosecurity measures available. It asks providers of synthesized DNA and manufacturers of synthesis machines to check synthesis requests for sequences of concern and to verify customer legitimacy before shipping orders. Providers should also record synthesis orders and sequence data to support legitimate biosecurity investigations, so that any threat that might evade initial screening can be traced back to its source — including when individual sequences would not raise concern in isolation. Awareness of traceability itself deters misuse.

Many of the largest and most responsible providers in the industry already screen and record orders voluntarily because it is well understood that they have an important role to play in maintaining public trust in and mitigating potential misuse of this important technology.

For these reasons, the undersigned support mandatory nucleic acid synthesis screening, including recordkeeping, in the United States. Given the pace at which the underlying technology is changing, we believe the need is urgent. Congress should act this session, and we applaud the legislative efforts currently underway. To ensure a consistent national standard rather than a patchwork of conflicting laws, states should also consider implementing requirements based on existing federal and industry guidelines.

This is a rare moment of agreement across stakeholders that are often at odds. We hope policymakers will meet it with decisive action.

Sincerely, Signatories

The undersigned —

Tech

Demis Hassabis CEO, Google DeepMind; Recipient of 2024 Nobel Prize in Chemistry

Sam Altman CEO and Co-Founder, OpenAI

Dario Amodei CEO and Co-Founder, Anthropic

Alexandr Wang Chief AI Officer, Meta; Founder, Scale AI

Paul Graham Founder, Y Combinator

Mustafa Suleyman CEO, Microsoft AI

Patrick Collison CEO and Co-Founder, Stripe

Martin E. Hellman Professor Emeritus of Electrical Engineering, Stanford University; Recipient of 2015 ACM Turing Award

Sayash Kapoor Researcher, Princeton University; Co-Author, AI Snake Oil; Co-Author, AI as Normal Technology

Peter Diamandis Founder and Executive Chairman, XPRIZE Foundation; Co-Founder and Executive Chairman, Singularity University; Co-Founder and Vice Chairman, Celularity

Eric Horvitz Chief Scientific Officer, Microsoft

Jason Kwon Chief Strategy Officer, OpenAI

Pushmeet Kohli Chief Scientist, Google Cloud; Vice President, Google DeepMind

Wojciech Zaremba Head of AI Resilience, OpenAI Foundation; Co-Founder, OpenAI

Geoff Ralston Founder, Safe AI Fund; Former President, Y Combinator

Nathan Lambert Founder and Researcher, Interconnects AI

Boaz Barak Member of Technical Staff, OpenAI; Professor, Harvard University

Aviya Skowron Head of Policy, EleutherAI

Jacob Trefethen Head of Life Sciences and Curing Diseases, OpenAI Foundation

Ben Brooks Affiliate, Berkman Klein Center, Harvard University

Nucleic Acid Synthesis Industry

Emily Leproust CEO and Co-Founder, Twist Bioscience

Jason T. Gammack CEO, Ansa Biotechnologies

James C. Diggans Vice President for Policy & Biosecurity, Twist Bioscience; Chair of the Board of Directors, International Gene Synthesis Consortium

Sridhar Govindarajan CTO, ATUM

Patrick Finn President and Chief Operating Officer, Twist Bioscience

Siyuan Chen Chief Technology Officer, Twist Bioscience

Daniel Lin-Arlow CSO and Co-Founder, Ansa Biotechnologies

Sebastian Palluk CTO and Co-Founder, Ansa Biotechnologies

DJ Kleinbaum Co-Founder, Emerald Cloud Lab

Kevin Flyangolts CEO and Founder, Aclid

Piers Millet Executive Director, International Biosecurity and Biosafety Initiative for Science (IBBIS)

Life Sciences and Biotechnology

David Baker Director, Institute for Protein Design; Henrietta and Aubrey Davis Endowed Professor of Biochemistry, University of Washington School of Medicine; Recipient of 2024 Nobel Prize in Chemistry

Drew Endy Bioengineer; Director for Bio-Strategies & Leadership, Hoover Institution, Stanford University

David Haussler Scientific Director, UC Santa Cruz Genomics Institute; Distinguished Professor, Biomolecular Engineering, UC Santa Cruz; Co-Founder, Global Alliance for Genomics and Health

Kathleen McMahon Co-Founder, Valthos

Sandeep Patel CEO and Founder, Catalyze; Former Director, BARDA DRIVe

John Glass Professor and La Jolla, CA Campus Director, J. Craig Venter Institute

David A. Relman Thomas C. and Joan M. Merigan Professor in Medicine, Stanford University

Hon. Mark R. Dybul Professor, Department of Medicine, Georgetown University Medical Center; Former Executive Director, the Global Fund to Fight AIDS, Tuberculosis and Malaria; Former United States Global AIDS Coordinator

Milana Trounce Clinical Professor in Emergency Medicine, Stanford University

Chris Somerville Professor Emeritus, University of California, Berkeley

Tom Inglesby Director, Johns Hopkins Center for Health Security, Johns Hopkins Bloomberg School of Public Health

Kevin Esvelt Associate Professor, MIT Media Lab

Becky Mackelprang Director for Security Programs, Engineering Biology Research Consortium

Hannu Rajaniemi

Co-Founder and CEO, HelixNano; Co-Founder, Red Queen Bio Nikolai Eroshenko

Co-Founder, HelixNano; Co-Founder and CEO, Red Queen Bio Matthew F. McKnight CEO, Perimeter

Gary Abel Chief Scientist and Co-Founder, Fourth Eon Biosecurity

Jacob Glanville Founder and CEO, Centivax

Rachel E. Levinson Visiting Scholar, Consortium for Science, Policy & Outcomes, Arizona State University

National Security and Policy

Gerald W. Parker Former Special Assistant to the President and Senior Director for Biosecurity and Pandemic Response, White House National Security Council

Hon. Christine E. Wormuth President and CEO, Nuclear Threat Initiative; 25th Secretary of the Army

RADM Kenneth Bernard (USPHS, Ret.) Former Special Assistant to the President for Biodefense

Hon. Richard Danzig 71st Secretary of the Navy

Hon. Andy Weber Former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs

Lawrence Lessig Roy L. Furman Professor of Law and Leadership, Harvard Law School

Alex T. Tabarrok Bartley J. Madden Chair in Economics, Mercatus Center; Professor of Economics, George Mason University

Abigail Ball Executive Director, American Compass

Tristan Harris Co-Founder, Center for Humane Technology

Zach Graves CEO and President, Foundation for American Innovation

Alec Stapp CEO and Co-Founder, Institute for Progress

Ian Mair CEO, Foundation for American Innovation Action

Dean W. Ball Senior Fellow, Foundation for American Innovation

Josh Wentzel Senior Fellow, Foundation for American Innovation

Mallory Stewart CEO, Council on Strategic Risks

Christine Parthemore Council on Strategic Risks

Jason Crawford Founder and President, Roots of Progress Institute

Claire Qureshi CEO and Co-Founder, Sentinel Bio

Joshua Monrad Co-Founder, Sentinel Bio

── more in #ai-safety 4 stories · sorted by recency
sponsored brought to you by zahid.host 4,200+ EU-deployed projects
reading about agents? ship yours in a single git push.

Run your AI side-project on zahid.host

EU-based hosting, git-push deploys, automatic HTTPS, no cold starts. Free tier with a custom domain — perfect for shipping the agent you just read about.

$git push zahid main
Live at https://your-agent.zahid.host
Get free account → Pricing
from €0/mo · no card required
LIVE [news/in-support-of-mandat…] indexed:0 read:6min 2026-06-04 ·